Literature DB >> 31454287

Motion Sickness Susceptibility and Baseline Vestibular and Ocular-Motor Performance in Adolescent Athletes.

R J Elbin1, Anthony P Kontos2, Alicia Sufrinko2, Mallory McElroy1, Katie Stephenson-Brown1, Samantha Mohler1, Nathan R D'Amico1, Michael W Collins2.   

Abstract

CONTEXT: High school athletes with a history of motion sickness susceptibility exhibit higher baseline vestibular and ocular-motor scores than those without a history of motion sickness susceptibility.
OBJECTIVE: To examine the effects of motion sickness susceptibility on baseline vestibular and ocular-motor functioning, neurocognitive performance, and symptom scores.
DESIGN: Cross-sectional study.
SETTING: Preseason concussion testing. PATIENTS OR OTHER PARTICIPANTS: A convenience sample of high school athletes (N = 308, age = 15.13 ± 1.21 years) involved in a variety of sports. MAIN OUTCOME MEASURE(S): Vestibular/Ocular Motor Screening, computerized neurocognitive assessment, symptom scale, and Motion Sickness Susceptibility Questionnaire-Short Form (MSSQ-S).
RESULTS: Participants were categorized into 3 groups based on a median split of the scores (eg, NONE, LOW, and HIGH). The LOW (n = 95) and HIGH (n = 92) groups (ie, MSSQ-S score > 0) were 2.64 times more likely (χ21,257 = 7.94, P = .01, 95% confidence interval = 1.32, 5.26) to have baseline Vestibular/Ocular Motor Screening scores larger than the clinical cutoffs for the NONE group (n = 70). No between-groups main effects were present for the NONE (n = 52), LOW (n = 89), and HIGH (n = 90) MSSQ-S groups for verbal (F2,230 = .09, P = .91, η2 = .001) and visual (F2,230 = .15, P = .86, η2 = .001) memory, processing speed (F2,230 = .78, P = .46, η2 = .007), or reaction time (F2,230 = 2.21, P = .11, η2 = .002). The HIGH group exhibited higher total baseline symptom scores than the LOW (U = 3325.50, z = -1.99, P = .05, r = .15) and NONE (U = 1647.50, z = -2.83, P = .005, r = .24) groups.
CONCLUSIONS: Motion sickness should be considered a preexisting risk factor that might influence specific domains of the baseline concussion assessment and postinjury management.

Entities:  

Keywords:  VOMS; baseline testing; concussion

Year:  2019        PMID: 31454287      PMCID: PMC6795099          DOI: 10.4085/1062-6050-347-18

Source DB:  PubMed          Journal:  J Athl Train        ISSN: 1062-6050            Impact factor:   2.860


  27 in total

1.  Interpreting change on ImPACT following sport concussion.

Authors:  Grant L Iverson; Mark R Lovell; Michael W Collins
Journal:  Clin Neuropsychol       Date:  2003-11       Impact factor: 3.535

2.  History of Somatization Is Associated with Prolonged Recovery from Concussion.

Authors:  Jeremy M Root; Noel S Zuckerbraun; Li Wang; Daniel G Winger; David Brent; Anthony Kontos; Robert W Hickey
Journal:  J Pediatr       Date:  2016-04-05       Impact factor: 4.406

3.  Sensitivity and specificity of the online version of ImPACT in high school and collegiate athletes.

Authors:  Philip Schatz; Natalie Sandel
Journal:  Am J Sports Med       Date:  2012-11-09       Impact factor: 6.202

4.  Vestibular Deficits following Youth Concussion.

Authors:  Daniel J Corwin; Douglas J Wiebe; Mark R Zonfrillo; Matthew F Grady; Roni L Robinson; Arlene M Goodman; Christina L Master
Journal:  J Pediatr       Date:  2015-03-05       Impact factor: 4.406

5.  Assessing the development of balance function in children using stabilometry.

Authors:  Ying-Shuo Hsu; Chen-Chieh Kuan; Yi-Ho Young
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2009-02-20       Impact factor: 1.675

6.  Effect of Gaze Stability Exercises on Chronic Motion Sensitivity: A Randomized Controlled Trial.

Authors:  Shilpa B Gaikwad; Eric G Johnson; Todd C Nelson; Oluwaseun I Ambode; Abdulaziz A Albalwi; Ahmad A Alharbi; Noha S Daher
Journal:  J Neurol Phys Ther       Date:  2018-04       Impact factor: 3.649

7.  Long-term test-retest reliability of baseline cognitive assessments using ImPACT.

Authors:  Philip Schatz
Journal:  Am J Sports Med       Date:  2009-09-29       Impact factor: 6.202

8.  A Brief Vestibular/Ocular Motor Screening (VOMS) assessment to evaluate concussions: preliminary findings.

Authors:  Anne Mucha; Michael W Collins; R J Elbin; Joseph M Furman; Cara Troutman-Enseki; Ryan M DeWolf; Greg Marchetti; Anthony P Kontos
Journal:  Am J Sports Med       Date:  2014-08-08       Impact factor: 6.202

9.  Measurement of symptoms following sports-related concussion: reliability and normative data for the post-concussion scale.

Authors:  Mark R Lovell; Grant L Iverson; Michael W Collins; Kenneth Podell; Karen M Johnston; Dustin Pardini; Jamie Pardini; John Norwig; Joseph C Maroon
Journal:  Appl Neuropsychol       Date:  2006

10.  Validity and Reliability of the Vestibular/Ocular Motor Screening and Associations With Common Concussion Screening Tools.

Authors:  Amy M Yorke; Laura Smith; Mitch Babcock; Bara Alsalaheen
Journal:  Sports Health       Date:  2016-11-11       Impact factor: 3.843

View more
  4 in total

1.  Vestibular and Ocular/Oculomotor Assessment Strategies and Outcomes Following Sports-Related Concussion: A Scoping Review.

Authors:  Carolina P Quintana; Tamara C Valovich McLeod; Anne D Olson; Nicholas R Heebner; Matthew C Hoch
Journal:  Sports Med       Date:  2021-01-05       Impact factor: 11.136

Review 2.  Pediatric Sports-Related Concussion: An Approach to Care.

Authors:  Olivia E Podolak; Kristy B Arbogast; Christina L Master; David Sleet; Matthew F Grady
Journal:  Am J Lifestyle Med       Date:  2021-01-21

3.  Effects of exercise on symptoms, vestibular/ocular motor screening and postural stability in a college-aged sample.

Authors:  Ryan N Moran; Nicholas G Murray; Michael R Esco; Ward Dobbs; Jamie McAllister-Deitrick
Journal:  Concussion       Date:  2020-05-14

4.  Postconcussion Exercise Volume Associations With Depression, Anxiety, and Dizziness Symptoms, and Postural Stability: Preliminary Findings.

Authors:  David R Howell; Danielle L Hunt; Jessie R Oldham; Stacey E Aaron; William P Meehan; Can Ozan Tan
Journal:  J Head Trauma Rehabil       Date:  2021-07-26       Impact factor: 3.117

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.